MedTrace Logo

Study to Evaluate the Immune Response of United Kingdom (UK) Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life

NCT00625677 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2019-03-22

No results posted yet for this study

Summary

The purpose of this study is:

To assess whether there are differences in antibody persistence eight months post primary (pre-booster) or in responses to the booster with regard to the Meningococcal C Conjugate (MCC) vaccine given in infancy.

To examine levels of diphtheria and tetanus antibody pre- and post-booster, with regard to the carrier proteins contained in the conjugate vaccines.

Conditions

  • Meningococcal Infections
  • Pneumococcal Infections

Interventions

BIOLOGICAL

NeisVacC (Meningococcal C conjugate vaccine)

Dosage

BIOLOGICAL

Menjugate (Meningococcal C conjugate vaccine)

Dosage

Sponsors & Collaborators

  • Institute of Child Health

    collaborator OTHER

  • National Institute of Biological Standards and Control

    collaborator OTHER_GOV

  • Public Health England

    lead OTHER_GOV

Principal Investigators

  • Elizabeth Miller, BSc MBBS FFPHM FRCPath · Public Health England

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
7 Weeks
Max Age
12 Weeks
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00625677 on ClinicalTrials.gov